
Biocept BIOC
Quartalsbericht 2023-Q2
hinzugefügt 14.08.2023
Biocept Betriebsaufwand 2011-2026 | BIOC
Betriebsaufwand Jährlich Biocept
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 21.6 M | 17.6 M | 17.5 M | 16.9 M | 14.3 M | 12.4 M | 11.8 M | 5.75 M | 9.41 M | 12.3 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 21.6 M | 5.75 M | 14 M |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
50.6 M | $ 1.59 | 1.27 % | $ 2.12 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 24.6 | -3.61 % | $ 683 M | ||
|
Fulgent Genetics
FLGT
|
181 M | $ 14.9 | -1.46 % | $ 451 M | ||
|
Agilent Technologies
A
|
1.99 B | $ 117.53 | 4.77 % | $ 35.7 B | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
CareDx, Inc
CDNA
|
411 M | $ 20.7 | -1.24 % | $ 1.1 B | ||
|
Illumina
ILMN
|
3.69 B | $ 139.07 | -0.22 % | $ 22.1 B | ||
|
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 85.82 | -2.23 % | $ 5.79 B | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Medpace Holdings
MEDP
|
118 M | $ 430.32 | 3.19 % | $ 12.4 B | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 9.27 | 1.98 % | $ 2.01 B | ||
|
National Research Corporation
NRC
|
38.5 M | $ 18.74 | 2.85 % | $ 419 M | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 121.32 | 8.35 % | $ 10 B | ||
|
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 26.45 | 0.8 % | $ 20 B | ||
|
Personalis
PSNL
|
44.5 M | $ 5.56 | -5.76 % | $ 329 M | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 185.39 | 7.58 % | $ 9.19 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
226 M | $ 89.52 | -1.81 % | $ 11.2 B | ||
|
Myriad Genetics
MYGN
|
964 M | $ 5.03 | 1.82 % | $ 466 M | ||
|
NeoGenomics
NEO
|
430 M | $ 8.86 | -1.56 % | $ 1.13 B | ||
|
Thermo Fisher Scientific
TMO
|
7.15 B | $ 466.76 | 0.9 % | $ 176 B | ||
|
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | ||
|
Interpace Biosciences
IDXG
|
20 M | $ 2.01 | 0.4 % | $ 8.89 M | ||
|
Senseonics Holdings
SENS
|
61.8 M | $ 5.0 | -0.2 % | $ 209 M | ||
|
Soleno Therapeutics
SLNO
|
181 M | $ 52.92 | 0.04 % | $ 2.69 B | ||
|
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
116 M | $ 56.7 | 0.91 % | $ 3.39 B | ||
|
Biomerica
BMRA
|
5.64 M | $ 2.19 | 1.16 % | $ 5.03 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 257.14 | 1.64 % | $ 21.4 B | ||
|
Celcuity
CELC
|
172 M | $ 141.69 | -2.27 % | $ 6.63 B | ||
|
Natera
NTRA
|
258 M | $ 206.77 | -2.26 % | $ 20.3 B | ||
|
Burning Rock Biotech Limited
BNR
|
726 M | $ 17.02 | -0.96 % | $ 180 M | ||
|
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 190.84 | -0.34 % | $ 21.2 B | ||
|
Waters Corporation
WAT
|
687 M | $ 342.75 | 13.54 % | $ 20.4 B |